Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 7/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416541 | 0.82 | DRD2 (0.50) | HSD17B1HSD17B2DRD2DRD1DRD4 | |
| SCHEMBL7128013 | 0.81 | PARP1 (0.46) | PARP1LTB4RLTB4R2 | |
| SCHEMBL12569388 | 0.81 | CTBP2 (0.54) | CTBP2PARP1TAAR1LTB4RLTB4R2 | |
| SCHEMBL11630519 | 0.80 | OPRK1 (0.51) | PARP1LTB4RLTB4R2 | |
| SCHEMBL5240155 | 0.80 | TAAR1 (0.51) | PARP1TAAR1 | |
| SCHEMBL12547971 | 0.80 | PARP1 (0.44) | PARP1LTB4RLTB4R2 | |
| SCHEMBL8561297 | 0.80 | HDAC6 (0.54) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL200141 | 0.79 | CTBP2 (0.56) | CTBP2ENPP2DRD2DRD1DRD4 | |
| SCHEMBL22981807 | 0.78 | CTBP2 (0.59) | CTBP2ENPP2DRD2DRD1CHRM2 | |
| SCHEMBL339507 | 0.78 | CES2 (0.56) | PARP1LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022212296-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101654-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, MAPKAP1, PIK3R5 | CTBP2 2738/4885HSD17B1 934/4885HSD17B2 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.